Dulaglutide Powder

Dulaglutide powder is a high-purity recombinant fusion protein API (active pharmaceutical ingredient) belonging to the GLP-1 receptor agonist family. Originally developed by Eli Lilly, it has become a core raw material for long-acting biopharmaceutical preparations in the biomedical industry. Different from ordinary small-molecule peptide raw materials, dulaglutide powder features unique molecular design, sophisticated manufacturing technology and strict quality control standards. Its core value lies in innovative structural research and mature industrial production technology, rather than simple therapeutic effects.Dulaglutide powder is a representative high-end biological API integrating innovative R&D design, sophisticated manufacturing technology and strict quality control. Its core value lies in the breakthrough of fusion protein structure technology, mature and stable industrial production process and scalable pharmaceutical research and development value. With the continuous development of domestic biological pharmacy technology, dulaglutide powder will further expand its application boundary in generic drug industrialization and new drug research and development, and continue to lead the technical upgrading of long-acting GLP-1 polypeptide raw materials.

Xi'an Sonwu Biotech Co., Ltd is a peptide raw material supplier with peptide technology at its core and an international market orientation. Sonwu is dedicated to the R&D, manufacturing, and worldwide distribution of bioactive peptide and polypeptide ingredients. Sonwu's products are widely applied in multiple fields, including muscle building, beauty and anti-aging, hair health, weight management, nootropics, and pharmaceutical raw materials.

Sonwu's products serve a global clientele, supporting both research and development and industrialization projects. Based on this, Sonwu has received a lot of feedback on Sonwu's products. Therefore, if you need dulaglutide, please contact Xi'an Sonwu.

Xi'an Sonwu not only provides large-scale production services but can also provide sample packages to customers first.

Xi'an Sonwu not only supplies high-quality dulaglutide, but can also customize products according to customer needs. In addition, Sonwu can provide customized packaging services, including repackaging products according to customer requirements.

1. Customized bottles(size, color, material, style)

2. Customized packaging(vacuum foil packaging, box, drum)

3. Customized label(paint film, matte film, optical mask)

Dulaglutide powder is a homodimer fusion protein with a molecular weight of 59.7 kDa, formed by linking two modified GLP-1 analogue fragments with a modified human IgG4 Fc segment via disulfide bonds. Its core technical mechanism stems from innovative molecular modification and structural optimization in R&D design. Native human GLP-1 is easily degraded by DPP-4 enzyme and cleared by the kidney, with an extremely short half-life, which limits its industrial application. In the R&D stage, researchers optimized the amino acid sequence of GLP-1 fragment to enhance anti-degradation ability, and fused it with IgG4 Fc fragment relying on protein engineering technology.

This structural design brings two core technical characteristics. First, the Fc fragment significantly increases the molecular volume, avoiding rapid glomerular filtration and reducing renal clearance efficiency. Second, it realizes FcRn-mediated cyclic recycling in vivo, effectively resisting enzymatic hydrolysis and degradation. Different from conventional peptide raw materials, dulaglutide powder does not rely on exogenous sustained-release accessories, but achieves long-acting characteristics through inherent molecular structure technology, which is the core technical breakthrough of its R&D design and lays a structural foundation for subsequent preparation development.

The advantages of dulaglutide powder are concentrated in industrial R&D and manufacturing technology, reflecting high technical barriers in biological raw material production. In terms of R&D logic, it abandons the traditional modification idea of single peptide optimization, and adopts an integrated design of peptide-protein fusion, realizing the organic combination of biological activity and structural stability. This innovative R&D framework has become a typical paradigm for the development of long-acting GLP-1 API raw materials, providing technical reference for the research and development of similar long-acting polypeptide drugs.

In terms of manufacturing technology, dulaglutide powder adopts mature recombinant eukaryotic expression process. Through stable cell line construction, targeted protein expression, precise cleavage and purification process optimization, it solves the technical problems of low yield, easy impurity generation and unstable structure of fusion protein raw materials. High-purity finished powder (industrial grade purity ≥98%) is obtained through multi-stage chromatographic purification, impurity removal and freeze-drying molding. Compared with ordinary polypeptide raw materials, its production process has higher precision requirements for temperature, pH value and purification parameters, with strong process controllability and batch stability.

In terms of quality system, dulaglutide powder implements the full-life cycle quality control standard of biological APIs. It conducts strict detection on structural modification impurities such as protein truncation, oxidation, hydroxylation and formylation, effectively controlling heterogeneous impurities generated in the production process. Its standardized quality system meets the technical evaluation requirements of domestic and foreign pharmacopoeias and drug regulatory guidelines, with high batch consistency and quality stability, which is the core advantage supporting its large-scale industrial application.

Compared with mainstream GLP-1 agonist raw materials such as semaglutide powder and liraglutide powder, dulaglutide powder has obvious technical and manufacturing differences. In terms of molecular technology, semaglutide relies on fatty acid chain modification to achieve long-acting effect, while dulaglutide adopts Fc fusion protein technology, with more stable molecular structure and lower dependence on auxiliary modification technology in production.

In terms of manufacturing difficulty, liraglutide is a single-chain modified polypeptide with relatively simple process, while dulaglutide, as a dimer fusion protein, has higher technical barriers in cell expression, dimer formation and impurity control, and better batch quality stability of finished powder. In terms of application adaptability, dulaglutide powder is more suitable for large-scale industrial production of long-acting fixed-dose preparations due to its stable structure and simple formulation process, while other similar raw materials have higher requirements for preparation process and storage conditions.

In terms of R&D scalability, dulaglutide's Fc fusion platform technology is highly scalable, which can be applied to the structural optimization of other polypeptide drugs, while the fatty acid modification technology of semaglutide has relatively single technical expansion space. Overall, dulaglutide powder has outstanding advantages in process stability, technical scalability and industrialization adaptability.

1. Xi'an Sonwu Biotech Co . Ltd has established a complete technology platform covering peptide molecular design, custom synthesis, precision purification, structural identification, and quality control. Strictly adhering to international quality management standards, the company ensures that its peptide raw materials meet the high-end raw material requirements of overseas customers in terms of purity, stability, and batch consistency.

2. Looking to the future, Sonwu will continue to deepen peptide technology innovation, expand Sonwu's global cooperation network, and strive to become a trusted long-term peptide raw material solution partner for international customers.

Besides guaranteeing the product, the most important thing is that customers receive the goods smoothly. So, Xi'an Sonwu offers a range of couriers to meet different needs.

The side effect characteristics of dulaglutide powder are essentially derived from the inherent biological activity of the molecule, not production quality problems. At the raw material level, high-purity dulaglutide powder has controllable impurity components and no exogenous harmful residues, with high safety of raw material attributes. The potential adverse reactions of downstream finished preparations are related to the pharmacological activity of GLP-1 receptor activation, including mild gastrointestinal discomfort and slight metabolic fluctuation, which are common class characteristics of GLP-1 agonist products, not individual quality defects of dulaglutide powder.

Benefiting from strict manufacturing and quality control technology, dulaglutide powder has extremely low abnormal impurity content, effectively avoiding adverse reactions caused by raw material impurities. Its stable molecular structure also reduces the risk of activity attenuation and impurity increase during storage and preparation processing, ensuring the safety and uniformity of downstream finished products.

If you want to find a dulaglutide supplier, contact Xi'an Sonwu. Click the email, and then you get high-quality products.

Email: sales02@sonwu.com

Hot Tags: dulaglutide powder, China dulaglutide powder manufacturers, suppliers, factory, pharmaceutical peptides, Piperlongumine Powder, TB500 Powder